Vistagen Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Phone 650-577-3600
Fiscal Year End 0331
EIN 205093315
Financial Overview
FY2025
-$29.36M
Net Income
$123.65M
Total Assets
$13.95M
Total Liabilities
$119.17M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 22, 2025 | View on SEC |
| 4 Insider stock transaction report | December 4, 2025 | View on SEC |
| 3 Initial insider ownership report | December 4, 2025 | View on SEC |
Material Events
8-K Financial Distress February 6, 2026
High Impact
- Vistagen is a clinical-stage biopharmaceutical company focused on treatments for anxiety, depression, and other CNS disorders.
- The company is actively exploring all options to regain Nasdaq compliance, including strategic financing or accelerating key clinical milestones.
8-K Other December 22, 2025
High Impact
- Vistagen Therapeutics' main anxiety drug, fasedienol, failed to meet its primary goal in the Phase 3 PALISADE-3 study for social anxiety disorder.
- Fasedienol did not show significant improvement in anxiety symptoms compared to a placebo.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.